Intravenous Mineralocorticoid Receptor Antagonist Use in Acutely Decompensated Heart Failure with Diuretic Resistance

Nicolas Girerd; Matthieu Aubry; Pierre Lantelme; Olivier Huttin; Patrick Rossignol

doi:10.1536/ihj.20-442

Case Reports

Intravenous Mineralocorticoid Receptor Antagonist Use in Acutely Decompensated Heart Failure with Diuretic Resistance

Nicolas Girerd, Matthieu Aubry, Pierre Lantelme, Olivier Huttin, Patrick Rossignol

著者情報

キーワード: Congestive heart failure, Furosemide, Dyspnea, Cardiac edema, Cardiovascular diseases, Potassium canrenoate

ジャーナルフリー

2021 年 62 巻 1 号 p. 193-196

DOI https://doi.org/10.1536/ihj.20-442

Browse “Advance online publication” version

詳細

抄録

Intravenous mineralocorticoid receptor antagonists (MRAs) have been used in some centers for decades to reduce the risk of hypokalemia and boost diuresis in acutely decompensated heart failure (ADHF). We report the well-tolerated use of intravenous MRAs as a rescue procedure in 3 patients admitted for ADHF with important diuretic resistance. Undertaking trials evaluating the effect of this therapeutic strategy in ADHF could represent a promising avenue.

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）